Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Evaluation of Treatment Outcomes after Second-Line Treatment Among Adult Patients with Immune Thrombocytopenia

Qayyim Said, PhD, Lincy S Lal, PhD, Brigette Nezami, PharmD, Katherine Andrade, J. Anthony Graves, MD, PhD, Anuja Roy, PhD, Adam Cuker, MD MS

Blood (2018) 132 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2018-99-115197

Published: 2018

Journal Articles

Bleeding Related Episodes, Thrombotic Events and Platelet Counts Among Immune Thrombocytopenia Patients Receiving Second Line Therapy

Qayyim Said, PhD, Lincy S Lal, PhD, Katherine Andrade, Brigette Nezami, PharmD, J. Anthony Graves, MD, PhD, Anuja Roy, PhD, Adam Cuker, MD MS

Blood (2018) 132 (Supplement 1): 2436.

https://doi.org/10.1182/blood-2018-99-111975

Published: 2018

Journal Articles

Comparing Costs and Consequences of Eltrombopag Plus IST Versus IST Alone for First-Line Treatment in Severe Aplastic Anemia: Results from a Responder Analysis

Gabriel Tremblay, DBA, MSc, BS, Qayyim Said, PhD, Beilei Cai, PhD MA, Shan Ashton Garib, MA, Dimitrios Tomaras, MSc, Anna Forsythe, PharmD, MSc, MBA, Anuja Roy, PhD

Blood (2018) 132 (Supplement 1): 1041.

https://doi.org/10.1182/blood-2018-99-115138

Published: 2018

Journal Articles

Benefit-Risk Comparison in Patients with Immune Thrombocytopenia (ITP) Receiving Eltrombopag or Romiplostim: Real World Evidence (RWE) from 26 Hospital Institutions

Anna Forsythe, PharmD, MSc, MBA, Anuja Roy, PhD, Menaka Bhor, PhD, Alex Allepuz, MD MPH, Maria Do Socorro Oliveira Portella, MD MBA, Christina Kwon, BSc, MSc, PhD, Gabriel Tremblay, DBA, MSc, BS

Blood (2017) 130 (Supplement 1): 3409.

https://doi.org/10.1182/blood.V130.Suppl_1.3409.3409

Published: 2017

Journal Articles

A Canadian Cost-Effectiveness Analysis for the Treatment of Immune Thrombocytopenia: Assessing the Relative Value of with Eltrombopag Versus Romiplostim

Gabriel Tremblay, DBA, MSc, BS, Mike Dolph, MSc BHSc, Anuja Roy, PhD, Juliette Neyra, PharmD, Khalid El Ouagari, Anna Forsythe, PharmD, MSc, MBA

Blood (2017) 130 (Supplement 1): 3410.

https://doi.org/10.1182/blood.V130.Suppl_1.3410.3410

Published: 2017

Journal Articles

Evaluation of Treatment Patterns Among Patients with Newly Diagnosed, Persistent, and Chronic Immune Thrombocytopenia (ITP) Treated with Eltrombopag in Real World Setting in the US

Dana Stafkey-Mailey, PharmD, PhD, Anuja Roy, PhD, Tasneem Lokhandwala, BPharm, MS, PhD, Jing Yuan, Pamela Landsman-Blumberg, MPH DrPH, Asif Siddiqui, PhD, Farhat Ghaznawi, MD

Blood (2017) 130 (Supplement 1): 2078.

https://doi.org/10.1182/blood.V130.Suppl_1.2078.2078

Published: 2017

Journal Articles

Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia

Gabriel Tremblay, DBA, MSc, BS, Menaka Bhor, PhD, Anuja Roy, PhD, Brian Elliott, MD, Mike Dolph, MSc BHSc, Anna Forsythe, PharmD, MSc, MBA, Andrew Briggs, DPhil

Blood (2017) 130 (Supplement 1): 2146.

https://doi.org/10.1182/blood.V130.Suppl_1.2146.2146

Published: 2017

Journal Articles

A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy

Regis Peffault De Latour, MD PhD, Lynn Huynh, Jasmina I. Ivanova, Todor Totev, BSc, Mehmet Bilginsoy, BA, Joseph H. Antin, MD, Anuja Roy, PhD, Mei Sheng Duh, MPH, ScD

Blood (2017) 130 (Supplement 1): 678.

https://doi.org/10.1182/blood.V130.Suppl_1.678.678

Published: 2017

Journal Articles

Value of Transfusion Independence in Severe Aplastic Anemia from Patients' Perspectives - a Discrete Choice Experiment

A. Simon Pickard, PhD, Jasmina I. Ivanova, Lynn Huynh, MPH, MBA, DrPh, Todor Totev, BSc, Sophia Graham, BA, Axel C Mühlbacher, PhD, Anuja Roy, Mei Sheng Duh

Blood (2016) 128 (22): 5077.

https://doi.org/10.1182/blood.V128.22.5077.5077

Published: 2016

Journal Articles

Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study

Mansoor N. Saleh, James B. Bussel, MD, Abderrahim Khelif, Paul Burgess, Ali El-Ali, Anuja Roy, Victoria Barghout, Mei Sheng Duh, Kelly M. Grotzinger, Abdulgabar Salama

Blood (2016) 128 (22): 3742.

https://doi.org/10.1182/blood.V128.22.3742.3742

Published: 2016

Journal Articles

Patient-Reported Health-Related Quality of Life Improves over Time in Patients with Chronic Immune Thrombocytopenia Receiving Long-Term Treatment with Eltrombopag

Abderrahim Khelif, Mansoor N. Saleh, Abdulgabar Salama, Paul Burgess, Maria do Socorro O Portella, Anuja Roy, Victoria Barghout, Jasmina I. Ivanova, Kelly M. Grotzinger, James B. Bussel, MD

Blood (2016) 128 (22): 3750.

https://doi.org/10.1182/blood.V128.22.3750.3750

Published: 2016

Journal Articles

Eltrombopag Compared to Rituximab Improves the Probability of Response in Adult Chronic ITP Patients

Alexander Hirst, MSc, Jing Wang-Silvanto, PhD, Cal Shephard, MSc, Anuja Roy, PhD

Blood (2016) 128 (22): 2334.

https://doi.org/10.1182/blood.V128.22.2334.2334

Published: 2016

Journal Articles

Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs

Sundar Jagannath, MD, Anuja Roy, PhD, Jonathan K Kish, PhDMPH, Denise Globe, PhD, Orsolya Lunacsek, PhDMBA, Michael T. Eaddy, PharmD, PhD, Emil T Kuriakose, MD, Joanne Willey, RN, David Siegel, MD PhD

Blood (2015) 126 (23): 3311.

https://doi.org/10.1182/blood.V126.23.3311.3311

Published: 2015

Journal Articles

Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma

Hongbo Yang, PhD, Anuja Roy, PhD, Chelsey Yang, Evangeline McDonald, Arun Krishna, PhD, Emil T Kuriakose, MD, Denise Globe, PhD, David Siegel, MD PhD, Sundar Jagannath, MD

Blood (2015) 126 (23): 5369.

https://doi.org/10.1182/blood.V126.23.5369.5369

Published: 2015

Journal Articles

Comparison of Real-World Treatment Patterns and Clinical Outcomes in 18-59 Year-Old Patients with FLT3 Mutated Vs. FLT3 Wild Type Acute Myeloid Leukemia: A Medical Records Review

Jipan Xie, MD PhD, Emily Goldmann, MPH, PhD, Anuja Roy, PhD MBA, Chelsey Yang, BA, Eric Q Wu, PhD, Carole Paley, MD

Blood (2014) 124 (21): 5992.

https://doi.org/10.1182/blood.V124.21.5992.5992

Published: 2014

NARROW

Evaluation of Treatment Outcomes after Second-Line Treatment Among Adult Patients with Immune Thrombocytopenia

Bleeding Related Episodes, Thrombotic Events and Platelet Counts Among Immune Thrombocytopenia Patients Receiving Second Line Therapy

Comparing Costs and Consequences of Eltrombopag Plus IST Versus IST Alone for First-Line Treatment in Severe Aplastic Anemia: Results from a Responder Analysis

Benefit-Risk Comparison in Patients with Immune Thrombocytopenia (ITP) Receiving Eltrombopag or Romiplostim: Real World Evidence (RWE) from 26 Hospital Institutions

A Canadian Cost-Effectiveness Analysis for the Treatment of Immune Thrombocytopenia: Assessing the Relative Value of with Eltrombopag Versus Romiplostim

Evaluation of Treatment Patterns Among Patients with Newly Diagnosed, Persistent, and Chronic Immune Thrombocytopenia (ITP) Treated with Eltrombopag in Real World Setting in the US

Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia

A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy

Value of Transfusion Independence in Severe Aplastic Anemia from Patients' Perspectives - a Discrete Choice Experiment

Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study

Patient-Reported Health-Related Quality of Life Improves over Time in Patients with Chronic Immune Thrombocytopenia Receiving Long-Term Treatment with Eltrombopag

Eltrombopag Compared to Rituximab Improves the Probability of Response in Adult Chronic ITP Patients

Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs

Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma

Comparison of Real-World Treatment Patterns and Clinical Outcomes in 18-59 Year-Old Patients with FLT3 Mutated Vs. FLT3 Wild Type Acute Myeloid Leukemia: A Medical Records Review

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only